Response to Comments: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

This document is a response-to-comments notice regarding MolDX LCD L39375 (Molecular Assays for Diagnosis of Cutaneous Melanoma) and does not itself state coverage criteria. The comment period ran 07/07/2022–08/20/2022; the LCD notice period begins 06/22/2023 and the LCD becomes effective 08/06/2023. No specific indications, limitations, documentation requirements, or frequency limits were provided in this response notice; manual review of the referenced LCD (L39375) is required to extract actionable coverage criteria.